Ovarian Cancer Clinical Trials in Boston

Showing 1-20 of 169 trials

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

NCT06964009

The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian cancer. The names of the study drugs involved in this study are: * DT2216 (a type of proteolysis-targeting chimera degrader of BCL-XL protein) * Paclitaxel (a type of antimicrotubule agent)

Ovarian CancerOvarian CarcinomaRecurrent Ovary Cancer+1 more

Elizabeth Stover, MD, PhD30 participantsStarted Sep 2025

Boston, Massachusetts, United States • Boston, Massachusetts, United States • Boston, Massachusetts, United States

Active Not RecruitingPhase 2< 1 mile

PF-07104091 as a Single Agent and in Combination Therapy

NCT04553133

To assess the safety and tolerability of increasing doses of PF-07104091 and to estimate the Maximum Tolerated Dose (MTD) and/or select the Recommended Phase 2 dose (RP2D) for PF-07104091 as a single agent in participants with advanced or metastatic small cell lung, breast and ovarian cancers.

Small Cell Lung CancerOvarian CancerBreast Cancer

Pfizer157 participantsStarted Sep 2020

Clive, Iowa, United States • Des Moines, Iowa, United States • Des Moines, Iowa, United States +43 more locations

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

PF-07104091 as a Single Agent and in Combination Therapy

Ovarian Cancer Trials in Other Cities

REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Other Conditions in Boston